Clinical Trials Browser

Active not recruiting × Neoplasms × mirvetuximab soravtansine × Clear all

NCT05445778 2026-06-02

GLORIOSA

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05456685 2025-10-28

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms